Skip to content

DappsAtlas index · 14,224 dApps

DappsAtlas

Comparison · Updated

Mitosis vs Veda: liquidity network or vault infrastructure (2026)

Mitosis is the more direct option for users exploring tokenized cross-chain liquidity. Veda is infrastructure for businesses building yield products, with much higher TVL but no obvious self-serve product.

Illustration for Mitosis vs Veda: liquidity network or vault infrastructure (2026)
Mitosis logo

Mitosis

Onchain Capital Allocator

Score 6.5 out of 10

TVL $1.25M · 12 chains

Veda logo

Veda

Onchain Capital Allocator

Score 7.6 out of 10

TVL $1.70B · 13 chains

Side by side

Mitosis vs Veda at a glance

Mitosis and Veda compared
 MitosisVeda
CategoryOnchain capital allocator; Layer 1 network for programmable liquidity positionsOnchain capital allocator; vault infrastructure for yield products
Operating modelUsers deposit into the Mitosis treasury and receive tokens representing depositsBusinesses use Veda to offer yield products through their own platforms
Chains12 listed chains13 listed chains
TVLAbout $1.3 millionAbout $1.79 billion
TokenMITO; project docs also describe gMITO governanceNo native token
FeesNot publishedNot published
Security and auditsTwo audits listed; auditors and findings not named hereTwo audits listed; security page covers audits and a bug bounty
Best fitFor users interested in tokenized, transferable LP positionsFor businesses building and operating Earn products
Standout featureCross-chain settlement and tokenized LP positionsVault infrastructure, operational console and partner revenue share
Key risksCross-chain contracts and relayers add risk; adoption and token economics matterVaults add strategy, underlying-market, partner and counterparty risks

How Mitosis and Veda differ

Mitosis and Veda both sit in onchain capital allocation, but they serve different users. Mitosis is a Layer 1 network built around turning liquidity positions into programmable assets that can move across chains. Users deposit into its treasury and receive tokens representing those deposits; LP positions can also be tokenized and traded. Veda supplies infrastructure for exchanges, wallets and protocols that want to offer yield products to their own users. Its tooling covers vault operations, monitoring, analytics and rebalancing, rather than presenting itself as a simple retail deposit app. The practical distinction is who the product is for: Mitosis is closer to a network and liquidity product that users can interact with, while Veda is a backend platform for businesses. Their TVL figures also differ sharply: about $1.3 million for Mitosis and about $1.79 billion for Veda. That gap is substantial, but it does not make the products interchangeable.

Features and supported chains

Both projects list 12 or more chains, but their multichain features have different roles. Mitosis lists 12 chains and aims to let users deposit once, then use tokenized positions across chains without separately bridging for each application. Its design depends on cross-chain settlement and the Mitosis network. Veda lists 13 chains for vault strategies, giving partner businesses infrastructure to offer products across networks. Its Earn Console is intended for operators managing analytics and day-to-day tasks such as rebalancing. Mitosis also describes targeted liquidity campaigns and composable infrastructure for DeFi applications. Veda emphasizes expandable vault strategies, access to lending markets and tokenized assets, and a revenue share for partners. Neither chain count tells you which specific asset, strategy or product is available to you, so check the relevant app or partner page. For users, the choice is less about one project having more networks and more about whether you want to use tokenized liquidity or a product built by a Veda partner.

Fees and yield

Neither project publishes a fee schedule here. Mitosis says costs for depositing, withdrawing or trading tokenized positions should be checked in its app and official docs; users should also expect gas fees on the chains they use. Its yield figures are not stated, so review live figures before committing funds. Veda also does not publish its fees. Because it serves partner businesses, costs may be set at the vault or partner level, and its fee terms could vary by product. Check each specific Earn page for management or performance fees, withdrawal costs and network gas. Veda says partners can capture a share of yield, but the revenue-share terms are not published. Do not assume that a product using either platform has a particular cost or return based on the infrastructure provider alone. Compare the terms of the exact position or vault you are considering, including how and when withdrawals work.

Safety and risks

Both projects have two audits listed, but neither names the auditors or describes audit findings here. Veda has a security page covering audits and a bug bounty, while Mitosis lists public documentation and a status page. Check the relevant project security materials before depositing; an audit count alone does not tell you what was reviewed or whether issues were resolved. Mitosis adds cross-chain smart-contract, messaging and settlement risks, and its homepage claim that applications cannot access user funds is not an independent verification. Veda vaults can expose funds to vault contracts, underlying lending markets or tokenized assets, and the partner operating the front end. Tokenized treasuries and institutional credit can add issuer and counterparty risk. Mitosis also says its TVL is small for a project aiming to serve as a broad liquidity layer, while Veda's activity is concentrated among a few large partners. Treat the two risk profiles as different, not as a simple safety ranking.

Which one should you choose?

Choose Mitosis if you want to explore tokenized LP positions and cross-chain liquidity as a user, and you understand that its TVL is about $1.3 million and its cross-chain design adds technical risk. Its listed MITO token and the project’s own chain and governance model may also matter to users who want exposure to that ecosystem. Choose Veda if you are a business looking to add a managed Earn product, or if you are evaluating a specific vault offered by one of its partners. Its much higher TVL, named partners and operator tooling are relevant to that infrastructure role, but do not mean every Veda-powered product has the same terms or risk. Veda is not the clearer choice for someone seeking a self-serve retail app. In either case, verify fees, strategy details, audit reports and withdrawal terms for the exact product before using it.

Verdict: Mitosis or Veda?

Pick Mitosis if you want to explore tokenized LP positions and cross-chain liquidity directly, and are comfortable with its small TVL and added cross-chain risks. Pick Veda if you are a business building an Earn product or evaluating a particular partner vault; its infrastructure, operator tooling and much higher TVL fit that use case. Veda is not an obvious self-serve option for retail users, while Mitosis is not a substitute for Veda’s business-facing vault platform. For either, check the exact product’s fees, strategy and withdrawal terms.

Frequently asked questions

Which supports more chains?

Mitosis lists 12 supported chains, while Veda lists 13. Their chains and purposes differ: Mitosis focuses on cross-chain liquidity positions, and Veda supports vault products.

Which has more TVL?

Veda has about $1.79 billion in TVL, compared with about $1.3 million for Mitosis. TVL alone does not show the risks or terms of a specific vault or position.

Are fees published?

Neither publishes a fee schedule in the information available here. Check the specific app or partner vault for its fees, and account for network gas costs.

Which is safer?

Both have two audits listed, but neither names the auditors or describes findings here. Veda has a security page covering audits and a bug bounty; Mitosis lists public docs and a status page.